A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients
a study on Hematological Malignancy
Hematological Malignancy invasive fungal disease Cresemba® isavuconazonium sulfate ASP9766 isavuconazole pediatric population Neoplasms isavuconazonium sulfate - intravenous isavuconazonium sulfate - oral
Lead Scientist at UCSF
- Janel Long-Boyle
Dr. Boyle is a translational scientist with research interests that include pediatric cancer therapeutics, pharmacokinetics, pharmacodynamics, pharmacogenomics, and clinical trial design.
- accepting new patients
- Start Date
- Completion Date
- Astellas Pharma Global Development, Inc.
- Phase 1
- Study Type
- Last Updated